source
- Gilead reports modest sales rise but analysts question future growth beyond HIV drugsGilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…
- Pfizer adds $2.5 billion to restructuring, targeting $6 billion savings by 2029Pfizer announced an additional $2.5 billion in cost reductions as part of its ongoing restructuring program. The new cuts focus on technology and simplification across commercial, R&D and manufact…